Abstract
To describe potential metrics of aging beyond chronological age and their associations with outcomes after solid organ transplantation. Investigation in this field has focused primarily on two areas: biomarkers related to replicative cell senescence and frailty and constructs related to frailty (e.g., sarcopenia, physical performance). Indicators of replicative senescence and frailty are more prevalent among transplant candidates than in the general elderly population, and both have been shown in recent studies to be associated with adverse outcomes following transplantation. Despite substantial evidence supporting the prognostic utility of these indicators, and of physical frailty in particular, no consensus has emerged about the best metric within individual organ specialty groups or across specialties. Research is ongoing to identify the most useful measure or set of measures.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
